Get Ready for Exciting News: Medicinova Launches Phase 2 Trial for MN-001 Tipelukast in NAFLD with Type 2 Diabetes and Hypertriglyceridemia!
Welcome to the MediciNova Phase 2 Trial Blog! Celebrating New Breakthroughs in Medical Research July 26, 2022 Hey there, readers! Have you heard the latest news from MediciNova, Inc.? They just announced the initiation of a Phase 2 clinical trial to evaluate MN-001 (tipelukast) for the treatment of patients with non-alcoholic fatty liver disease (NAFLD)…